<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046356</url>
  </required_header>
  <id_info>
    <org_study_id>SWH-66</org_study_id>
    <secondary_id>SouthwestH</secondary_id>
    <nct_id>NCT02046356</nct_id>
  </id_info>
  <brief_title>Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation</brief_title>
  <official_title>Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation: a Multi-center Prospective Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yunhua Tan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim was to investigate the efficacy of radiofrequency ablation (RFA) with a&#xD;
      multiple-electrode switching system (MESS) in the treatment of early hepatocellular carcinoma&#xD;
      (HCC) and to evaluate the patterns and risk factors of intrahepatic recurrence of HCC after&#xD;
      RFA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous RFA has become a particularly promising treatment for patients with early HCC.&#xD;
      For HCC with a diameter less than 3cm, RFA is becoming an effective topical method for the&#xD;
      goal of a complete cure. Although RFA is successful for small HCCs, for HCCs with a diameter&#xD;
      larger than 3 to 5 cm, the complete ablation rate is reported to range from 61.3% to 82.5%.&#xD;
      These results may be obsolete due to the further development of RFA techniques and&#xD;
      instruments. For example, the use of clustered electrodes and an improved motor can provide a&#xD;
      higher power, and the multiple-electrode switching system RFA (MESS-RFA) uses various methods&#xD;
      to create a sufficient ablation zone, the investigators need to further update the management&#xD;
      strategy of the RFA treatment of early HCC.&#xD;
&#xD;
      However, HCC recurrence after RFA is still a significant problem . the investigators divide&#xD;
      the intrahepatic recurrence after RFA into local tumor progression (LTP) and intrahepatic&#xD;
      distant recurrence (IDR); each type of recurrence has a different pathogenic mechanism and is&#xD;
      thought to occur relatively independently . Understanding the pattern and risk factors of&#xD;
      recurrence is very important for the development of RFA and its clinical application.&#xD;
&#xD;
      The objective of our multicenter prospective study was to evaluate the efficacy of MESS-RFA&#xD;
      as a primary method for treating early HCC, to assess the pattern of intrahepatic recurrence&#xD;
      according to the types of recurrence, and to determine the risk factors associated with tumor&#xD;
      recurrence and survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Technical success</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Complete ablation rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LTP</measure>
    <time_frame>up to 5 years</time_frame>
    <description>local tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDR</measure>
    <time_frame>up to 5 years</time_frame>
    <description>intrahepatic distant recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Overall survival rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDR-free survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>IDR-free survival rates</description>
  </secondary_outcome>
  <other_outcome>
    <measure>RFA complications</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Complication rate</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">139</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Early-Stage HCC</arm_group_label>
    <description>Early-Stage hepatocellular carcinoma From January 2014 to January 2015, a total of 139 patients with early HCC from the First Affiliated Hospital, the Second Affiliated Hospital and the Third Affiliated Hospital of the Third Military Medical University were prospectively recruited according after MESS-RFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MESS-RFA</intervention_name>
    <arm_group_label>Early-Stage HCC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In-patients from three affiliated hospital of the Third Military Medical University&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years old&#xD;
&#xD;
          -  The diameter of single tumor should be no more than 5cm, or multiple tumors(less than&#xD;
             3 loci) should be no more than 3cm. No large vascular invasion, no lymph nodes or&#xD;
             extrahepatic metastases&#xD;
&#xD;
          -  The Classification of patients' liver function is Child - Pugh A or B&#xD;
&#xD;
          -  No serious coagulation dysfunction (prothrombin activity &lt; 40% or platelet count &lt;&#xD;
             30000 / mL).&#xD;
&#xD;
          -  No refractory ascites.&#xD;
&#xD;
          -  The patients can be treated with RFA in clinical&#xD;
&#xD;
          -  Primary treatment by RFA should ablate the tumor(s) completely&#xD;
&#xD;
          -  The patients are aware of their condition, the treatment of the HCC, and the risks&#xD;
             associated with radiofrequency ablation therapy.&#xD;
&#xD;
          -  The patients participant voluntarily and they will sign the informed consent before&#xD;
             the radiofrequency ablation therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patients are from abroad, Hong Kong, Macao, Taiwan and other regions, who are&#xD;
             impossible to be follow-up&#xD;
&#xD;
          -  The patients who refuse to sign the informed consent&#xD;
&#xD;
          -  Tumor emboli existed in main portal vein, ductus hepatics communis and(or) its primary&#xD;
             branch, main hepatic vein and(or) inferior vena cava before operation&#xD;
&#xD;
          -  Extrahepatic metastasis, lymph node metastasis&#xD;
&#xD;
          -  The patients whom accept systemic chemotherapy, preoperative interventional therapy,&#xD;
             and(or) other auxiliary treatment&#xD;
&#xD;
          -  The patients with diabetes mellitus, heart disease and(or) other diseases can't&#xD;
             tolerate radiofrequency ablation, or influence postoperative follow-up&#xD;
&#xD;
          -  The existence of other type of malignant tumor before or accompanied by HCC&#xD;
&#xD;
          -  Primary treatment by RFA do not ablate the tumor(s) completely&#xD;
&#xD;
          -  Non-primary liver tumor, such as the liver metastatic carcinoma, cholangiocarcinoma,&#xD;
             etc&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunhua Tan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hospital, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.xnyy.cn/</url>
    <description>Southwest Hospital,China</description>
  </link>
  <reference>
    <citation>Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012 Apr;107(4):569-77; quiz 578. doi: 10.1038/ajg.2011.425. Epub 2011 Dec 13.</citation>
    <PMID>22158026</PMID>
  </reference>
  <reference>
    <citation>Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000 Dec;32(6):1224-9.</citation>
    <PMID>11093728</PMID>
  </reference>
  <reference>
    <citation>Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008 Oct;49(4):589-94. doi: 10.1016/j.jhep.2008.05.018. Epub 2008 Jun 12.</citation>
    <PMID>18620773</PMID>
  </reference>
  <reference>
    <citation>Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg. 2008 Jan;12(1):183-91. Epub 2007 Sep 15.</citation>
    <PMID>17874276</PMID>
  </reference>
  <reference>
    <citation>Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008 Jul;207(1):20-9. doi: 10.1016/j.jamcollsurg.2008.01.020. Epub 2008 Apr 24.</citation>
    <PMID>18589357</PMID>
  </reference>
  <reference>
    <citation>Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010 Jul;78 Suppl 1:113-24. doi: 10.1159/000315239. Epub 2010 Jul 8. Review.</citation>
    <PMID>20616593</PMID>
  </reference>
  <reference>
    <citation>Lee HY, Rhim H, Lee MW, Kim YS, Choi D, Park MJ, Kim YK, Kim SH, Lim HK. Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors. Eur Radiol. 2013 Jan;23(1):190-7. doi: 10.1007/s00330-012-2561-8. Epub 2012 Oct 20.</citation>
    <PMID>23085860</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Yunhua Tan</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>Milan Criteria</keyword>
  <keyword>recurrence</keyword>
  <keyword>risk factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

